<DOC>
	<DOCNO>NCT00347217</DOCNO>
	<brief_summary>Observational study investigate use efficacy CRESTOR 5 mg reach LDL-C target goal statin na√Øve statin treat primary secondary prevention patient high risk cardiovascular event .</brief_summary>
	<brief_title>Observational Investigate Efficacy CRESTOR 5mg Reaching LDL-C Target Goals Patients Who Are High Risk Cardiovascular Event</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>The patient high risk cardiovascular event define European guideline . The patient statinnaive ( i.e . use statin &gt; 2 month ) , currently treat atorvastatin , pravastatin simvastatin . An LDLC level know statinnaive patient statin use visit 1 . It decide start patient CRESTOR 5 mg . The patient prepare give permission cod data make available AstraZeneca The patient know complaint myalgia , myopathy liver function impairment ( include elevate level serum transaminase ) causal relationship statin treatment . Contraindications treatment CRESTOR ( see 1 B1 text ) . Patients family history dyslipidemias , instance familiar ( combine ) hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>LDL-C goal</keyword>
	<keyword>observational study</keyword>
	<keyword>primary prevention</keyword>
	<keyword>secondary prevention</keyword>
</DOC>